$50.2 M

ITEK Mkt cap, 22-Dec-2017
Inotek Pharmaceuticals Net income (Q1, 2018)-15.3 M
Inotek Pharmaceuticals EBIT (Q1, 2018)-14.4 M
Inotek Pharmaceuticals Cash, 31-Mar-2018171.1 M

Inotek Pharmaceuticals Financials

Inotek Pharmaceuticals Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

R&D expense

12.6 m32 m14.2 m

General and administrative expense

7.8 m9.9 m12.5 m

Operating expense total

20.4 m41.9 m26.7 m

EBIT

(20.4 m)(41.9 m)(26.7 m)

Interest expense

1.2 m1.4 m3.6 m

Interest income

89 k443 k819 k

Net Income

(68 m)(42.9 m)(29.5 m)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

R&D expense

1.1 m2 m3.6 m7.6 m6.5 m8.4 m7.1 m3.6 m5.7 m

General and administrative expense

2 m1.7 m1.8 m2.5 m2.3 m2.3 m2.9 m2.2 m8.7 m

Operating expense total

3 m3.7 m5.4 m10.1 m8.8 m10.7 m10 m5.9 m14.4 m

EBIT

(3 m)(3.7 m)(5.4 m)(10.1 m)(8.8 m)(10.7 m)(10 m)(5.9 m)(14.4 m)

Interest expense

474 k564 k192 k474 k564 k525 k876 k889 k1.4 m

Interest income

33 k69 k96 k120 k172 k183 k288 k

Net Income

(1.5 m)(2.4 m)(56 m)(10.1 m)(8.7 m)(11.1 m)(10.7 m)(6.6 m)(15.3 m)

Inotek Pharmaceuticals Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

80 m29.8 m78.7 m

Inventories

1.1 m1.9 m

Current Assets

112.4 m128.3 m101 m

PP&E

812 k1.1 m563 k

Total Assets

113.3 m129.6 m101.8 m

Accounts Payable

1.6 m1.6 m451 k

Current Liabilities

4.1 m7.2 m4.1 m

Total Liabilities

56.5 m54 m

Additional Paid-in Capital

304.6 m311.8 m316.1 m

Retained Earnings

(196 m)(238.9 m)(268.4 m)

Total Equity

108.8 m73.2 m47.8 m

Financial Leverage

1 x1.8 x2.1 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

53.1 m49 m89.2 m58.7 m38.5 m83 m25.3 m27.6 m171.1 m

Current Assets

53.4 m49.5 m119.2 m103.2 m98.7 m138.9 m116.6 m109.8 m184.8 m

PP&E

29 k756 k790 k976 k1 m1.1 m1.1 m1.1 m

Goodwill

30.8 m

Total Assets

55.5 m51.7 m120.1 m104.2 m99.9 m140.1 m117.9 m111.1 m217.2 m

Accounts Payable

1.3 m813 k1.7 m1.4 m921 k1.8 m1.9 m368 k168 k

Current Liabilities

2.5 m2.5 m3.2 m4.6 m4.1 m5.9 m5.3 m4 m7.3 m

Total Liabilities

21.6 m20 m3.6 m5 m4.4 m55.1 m54.7 m53.5 m47 m

Additional Paid-in Capital

163.3 m163.4 m304.1 m305.1 m309.9 m310.7 m312.6 m313.4 m216.4 m

Retained Earnings

(129.5 m)(131.9 m)(187.9 m)(206.1 m)(214.8 m)(225.9 m)(249.5 m)(256.1 m)(46.7 m)

Total Equity

34 m31.7 m116.5 m99.2 m95.4 m85.1 m63.3 m57.5 m170.1 m

Financial Leverage

1.6 x1.6 x1 x1.1 x1 x1.6 x1.9 x1.9 x1.3 x

Inotek Pharmaceuticals Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

(68 m)(42.9 m)(29.5 m)

Depreciation and Amortization

45 k169 k200 k

Accounts Payable

487 k(41 k)(1.1 m)

Cash From Operating Activities

(17.4 m)(37.3 m)(26.1 m)

Purchases of PP&E

(412 k)(487 k)(70 k)

Cash From Investing Activities

(31.7 m)(66.1 m)75 m

Short-term Borrowings

(5.8 m)(5.8 m)

Cash From Financing Activities

125.5 m53.1 m

Interest Paid

89 k89 k3 m

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(1.5 m)(2.8 m)(56 m)(10.1 m)(18.8 m)(29.9 m)(10.7 m)(17.2 m)(15.3 m)

Depreciation and Amortization

6 k37 k72 k111 k61 k124 k83 k

Accounts Payable

154 k(333 k)563 k(257 k)(712 k)144 k310 k(1.2 m)(2.3 m)

Cash From Operating Activities

(2 m)(6.1 m)(10.4 m)(9 m)(17 m)(26.1 m)(11.6 m)(17.5 m)(11.6 m)

Purchases of PP&E

(30 k)(318 k)(15 k)(236 k)(344 k)(53 k)(70 k)(8 k)

Cash From Investing Activities

(30 k)(29.4 m)(12.3 m)(28.7 m)(23.8 m)7.1 m15.3 m86.1 m

Short-term Borrowings

(5.8 m)(5.8 m)(5.8 m)(5.8 m)(5.8 m)

Cash From Financing Activities

51.5 m51.5 m125.4 m51.5 m4.2 m52.9 m35 k

Interest Paid

89 k89 k89 k89 k89 k89 k1.5 m1.5 m1.5 m

Inotek Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

1.3 x
Report incorrect company information

Inotek Pharmaceuticals Operating Metrics

FY, 2016

Patent Portfolios

1

Phase III Trials Products

1
Report incorrect company information